



Update on VB10.NEO

November 8, 2024



Forward-looking statement

This announcement and any materials distributed in connection with this presentation may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.



VB10.NEO- Nykode's individualized cancer vaccine










- VB10.NEO is a fully individualized cancer vaccine.
- Nykode has held a global license and collaboration agreement with Genentech since September 2020.
- VB10.NEO has been tested in 2 clinical trials, N-01 and N-02, in recurrent/metastatic patients across >10 solid tumors types.
 - N-02 has been designed and conducted in collaboration with Genentech and is in its final stage.



Nykode regains control of VB10.NEO

- Received notification of termination from Genentech effective Jan 6, 2025
- Nykode regains **control of VB10.NEO and its intellectual property**, enabling independent strategic decisions for the program's future
- No requirement to refund any upfront payments or make any future payments to Genentech
- Notice of termination does not reference clinical data or aspects related to technology platform
- Nykode remain convinced of the **potential of VB10.NEO and its ability to generate uniquely broad patient- and tumor-specific immune responses**
- **Nykode will determine the best path forward for the program, including potential new partnerships**

Broad pipeline

	Asset	Indication	Rights	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Catalyst
Oncology								
Off-the-shelf	VB10.16	HPV16+ cervical cancer	 ¹	<div><div></div></div>			C-02	Publication of final data
		HPV16+ head and neck cancer	 ²	<div><div></div></div>	C-03		Dose level recommendation (2H 2024)	
		HPV16+ locally advanced cervical cancer	 ²	<div><div></div></div>		C-05	Protocol in development. Final design in 2H	
	Regeneron programs	Undisclosed	  ³	<div><div></div></div>			Selection of lead candidate	
Individualized	VB10.NEO	Incurable locally advanced and metastatic tumors		<div><div></div></div>		N-02		
Infectious Disease								
Regeneron programs		Undisclosed	  ³	<div><div></div></div>				
Autoimmune								
Internal		Undisclosed		<div><div></div></div>				Update in Q4

1. Wholly-owned by Nykode. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron

QUESTIONS?

UNLOCKING THE FUTURE OF MEDICINE

Contact:
Alexandra Deschner
Head of Investor Relations
IR@nykode.com